» Articles » PMID: 38255891

The Importance of Complement-Mediated Immune Signaling in Alzheimer's Disease Pathogenesis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jan 23
PMID 38255891
Authors
Affiliations
Soon will be listed here.
Abstract

As an essential component of our innate immune system, the complement system is responsible for our defense against pathogens. The complement cascade has complex roles in the central nervous system (CNS), most of what we know about it stems from its role in brain development. However, in recent years, numerous reports have implicated the classical complement cascade in both brain development and decline. More specifically, complement dysfunction has been implicated in neurodegenerative disorders, such as Alzheimer's disease (AD), which is the most common form of dementia. Synapse loss is one of the main pathological hallmarks of AD and correlates with memory impairment. Throughout the course of AD progression, synapses are tagged with complement proteins and are consequently removed by microglia that express complement receptors. Notably, astrocytes are also capable of secreting signals that induce the expression of complement proteins in the CNS. Both astrocytes and microglia are implicated in neuroinflammation, another hallmark of AD pathogenesis. In this review, we provide an overview of previously known and newly established roles for the complement cascade in the CNS and we explore how complement interactions with microglia, astrocytes, and other risk factors such as TREM2 and ApoE4 modulate the processes of neurodegeneration in both amyloid and tau models of AD.

Citing Articles

Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer's Disease.

Lee E, Chang Y Cells. 2025; 14(3).

PMID: 39936960 PMC: 11817173. DOI: 10.3390/cells14030168.


Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer's Disease.

Sharo C, Zhang J, Zhai T, Bao J, Garcia-Epelboim A, Mamourian E Targets (Basel). 2025; 2(4):446-469.

PMID: 39897171 PMC: 11786951. DOI: 10.3390/targets2040025.


Synapse vulnerability and resilience underlying Alzheimer's disease.

Taddei R, E Duff K EBioMedicine. 2025; 112:105557.

PMID: 39891995 PMC: 11833146. DOI: 10.1016/j.ebiom.2025.105557.


Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease.

Marta-Ariza M, Leitner D, Kanshin E, Suazo J, Giusti Pedrosa A, Thierry M Acta Neuropathol. 2025; 149(1):9.

PMID: 39825890 PMC: 11742868. DOI: 10.1007/s00401-025-02844-z.


Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms.

Greenberg S, Bax F, van Veluw S Nat Rev Neurol. 2025; .

PMID: 39794509 DOI: 10.1038/s41582-024-01053-8.


References
1.
McGeer P, Itagaki S, TAGO H, McGeer E . Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987; 79(1-2):195-200. DOI: 10.1016/0304-3940(87)90696-3. View

2.
Bellenguez C, Kucukali F, Jansen I, Kleineidam L, Moreno-Grau S, Amin N . New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022; 54(4):412-436. PMC: 9005347. DOI: 10.1038/s41588-022-01024-z. View

3.
Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard A, Rollin-Sillaire A . TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis. 2013; 35(1):45-9. DOI: 10.3233/JAD-122311. View

4.
Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

5.
Ishii T, Haga S . Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol. 1984; 63(4):296-300. DOI: 10.1007/BF00687336. View